APOA1 and diabetes mellitus: The first direct evidence that HDLs and apoA-I have potential therapeutic value in humans with diabetes came from the aforementioned study in which a single infusion of rHDLs prepared with apoA-I and soybean phosphatidylcholine improved glycaemic control in patients with T2D [62].